F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comKrsnaa Diagnostics Ltd, a fast-growing diagnostics services provider in India, has carved a niche for itself by offering affordable, technology-enabled diagnostic solutions across the country. As of May 21, 2025, Krsnaa Diagnostics is trading at ₹643.00 with a market capitalization of ₹2,055 crore. In this article, we will explore the current market performance, shareholding pattern, and projected share price targets for Krsnaa Diagnostics from 2025 to 2030.
Let’s start by examining the key performance indicators of Krsnaa Diagnostics as of the latest market data:
Open Price: ₹643.00
Previous Close: ₹634.10
Volume: 82,167 shares
Value (Lacs): ₹523.08
VWAP (Volume Weighted Average Price): ₹642.82
Beta: 1.19
Market Capitalization: ₹2,055 Crore
High: ₹652.80
Low: ₹632.05
Upper Circuit Limit: ₹760.90
Lower Circuit Limit: ₹507.30
52-Week High: ₹1,044.00
52-Week Low: ₹528.05
Face Value: ₹5
All-Time High: ₹1,099.70
All-Time Low: ₹353.10
Currently, Krsnaa Diagnostics is trading close to its recent lows, signaling potential for recovery. The significant gap between its 52-week high and current price indicates a correction phase, but also sets the stage for future upside given favorable conditions.
Understanding the shareholding structure offers insights into investor confidence and institutional interest:
Retail and Others: 54.94%
Promoters: 27.24%
Mutual Funds: 9.36%
Other Domestic Institutions: 4.90%
Foreign Institutions: 3.55%
Retail investors hold a majority, suggesting high public interest. Promoter holding at 27.24% shows a decent level of insider confidence, while institutional holdings reflect growing trust in the company’s long-term potential.
Based on current performance, market trends, and the company’s growth trajectory, here’s a forecast of Krsnaa Diagnostics' share price targets from 2025 to 2030:
| Year | Share Price Target (₹) |
|---|---|
| 2025 | 643.00 – 760.90 |
| 2026 | 760.90 – 880.00 |
| 2027 | 880.00 – 1,000.00 |
| 2028 | 1,000.00 – 1,120.00 |
| 2029 | 1,120.00 – 1,200.00 |
| 2030 | 1,200.00 – 1,300.00 |
In 2025, the price is expected to stabilize between ₹643.00 and ₹760.90. Growth may stem from:
Expansion into underserved rural and semi-urban regions.
Increased adoption of preventive healthcare in India.
Higher testing volumes post-pandemic as routine diagnostics become a norm.
By 2026, Krsnaa Diagnostics is likely to benefit from:
Public-private partnerships with state governments for diagnostic infrastructure.
A surge in radiology and pathology test demand due to better health awareness.
Strengthened financials with improved margins from economies of scale.
The 2027 target hinges on:
Expansion of automated labs and digital report delivery models.
Stronger penetration in tier-II and tier-III cities.
Listing of newer diagnostics technologies and real-time testing models.
By 2028, expected gains may be attributed to:
A broader service portfolio including genomics, wellness, and lifestyle testing.
Robust revenue from long-term institutional tie-ups.
Sustainable growth in EBITDA margins.
Krsnaa’s price movement in 2029 may be driven by:
Steady customer acquisition via digital marketing and e-health platforms.
Expansion into international markets through collaborations.
Innovation in AI-driven diagnostics and smart health devices.
The company’s long-term trajectory could place the stock between ₹1,200.00 and ₹1,300.00 by 2030, thanks to:
Technological leadership in diagnostic automation and real-time analytics.
Dominance in affordable diagnostics across India.
Strong balance sheet and recurring revenues from contracts and diagnostics-as-a-service models.
Several factors will impact the future price performance of Krsnaa Diagnostics:
Healthcare Growth: Rising demand for diagnostics in India’s growing population.
Government Support: National health initiatives like Ayushman Bharat and public diagnostics schemes.
Operational Scalability: Ability to manage costs while expanding across India.
Technological Edge: Investment in AI-based diagnostic tools and real-time data sharing.
Despite the positive outlook, some risks remain:
High Competition: From both organized players like Dr. Lal PathLabs, Metropolis, and Thyrocare.
Regulatory Risks: Price controls or changes in healthcare policies could affect margins.
Execution Delays: Project and partnership execution delays can impact revenues.
Market Sentiment: General investor mood in mid-cap healthcare stocks may cause volatility.
The projected range is ₹643.00 to ₹760.90, supported by healthcare sector growth and geographic expansion.
If you're looking for a long-term player in India's diagnostic services space with high growth potential, Krsnaa Diagnostics is worth considering. However, monitor regulatory changes and competition.
Retail investors hold 54.94%, while promoters and institutions account for the rest—signaling balanced interest across investor classes.
Yes, if the company continues to expand its footprint, invests in technology, and improves profitability, the stock has the potential to reach or exceed ₹1,000 by 2027.
Krsnaa Diagnostics Ltd is positioned to benefit from India’s growing focus on affordable and accessible healthcare. The company’s widespread presence, cost-efficient operations, and promising financial outlook make it a strong candidate for long-term investment. With share price targets projecting steady growth up to ₹1,300 by 2030, investors can consider this stock for portfolio diversification within the healthcare sector—while being mindful of regulatory and competitive risks.
Register & Login